Hier finden Sie grundlegende Angaben zu klinischen Studien des Comprehensice Cancer Centers Mainfranken (CCC MF)
Filter aktiv
Seite 1 - Studien 1 bis 4 von insgesamt 4
- Rekrutierung läuftA phase 1/1b/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AMG 193 alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumorsIndikationen
- Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)
- Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)
- Bauchspeicheldrüsenkrebs (Pankreaskarzinom)
- Lungentumoren
- Nicht-kleinzelliges Bronchialkarzinom (NSCLC)
- Kopf/Hals Tumoren
- Kopf-Hals-Malignome
- Rekrutierung läuftA Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAPdeletion
(Master Protocol)Molekulare Marker - Rekrutierung läuft
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 in Combination With other Therapies in Subjects With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous MTAP-deletion
Subprotocol A: AMG 193 in Combination with Gemcitabine, Cisplatin, and Pembrolizumab in Subjects with Advanced BTC With Homozygous MTAP-deletion
Subprotocol B: AMG 193 in Combination with mFOLFIRINOX or with Gemcitabine and Nab-paclitaxel in Subjects with Advanced PDAC with Homozygous MTAP-deletion
Molekulare Marker - Rekrutierung läuftNon-Hodgkin Lymphoma: Epcoritamab in Combination with Anti-Neoplastic AgentsMolekulare Marker